These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 6171523

  • 1. Increased vasoactive mediator releasability: a possible pathogenic factor of atopic dermatitis.
    Ring J.
    Int Arch Allergy Appl Immunol; 1981; 66 Suppl 1():156-8. PubMed ID: 6171523
    [No Abstract] [Full Text] [Related]

  • 2. Basophil histamine release and leukotriene production in response to anti-IgE and anti-IgE receptor antibodies. Comparison of normal subjects and patients with urticaria, atopic dermatitis or bronchial asthma.
    Bischoff SC, Zwahlen R, Stucki M, Müllner G, de Weck AL, Stadler BM, Dahinden CA.
    Int Arch Allergy Immunol; 1996 Jul; 110(3):261-71. PubMed ID: 8688673
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE-syndrome.
    Ruzicka T, Glück S.
    Arch Dermatol Res; 1983 Jul; 275(1):41-4. PubMed ID: 6189456
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Canine leucocyte histamine release: response to antigen and to anti-IgE.
    Jackson HA, Miller HR, Halliwell RE.
    Vet Immunol Immunopathol; 1996 Oct; 53(3-4):195-206. PubMed ID: 8969041
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunopharmacology of the atopic diseases.
    Hanifin JM, Butler JM, Chan SC.
    J Invest Dermatol; 1985 Jul; 85(1 Suppl):161s-164s. PubMed ID: 2409183
    [Abstract] [Full Text] [Related]

  • 15. Ultraviolet A inhibits histamine release from human peripheral leukocytes.
    Ring J, Przybilla B, Eberlein B.
    Int Arch Allergy Appl Immunol; 1989 Jul; 88(1-2):136-8. PubMed ID: 2468613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.
    Ramírez del Pozo ME, Contreras Contreras E, López Tiro J, Gómez Vera J.
    J Investig Allergol Clin Immunol; 2011 Jul; 21(5):416-7. PubMed ID: 21905512
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.